Go Pro
NASDAQ:VINC

Vincerx Pharma (VINC) Stock Price, News & Analysis

Vincerx Pharma logo
$0.02 0.00 (0.00%)
As of 09/23/2026 09:30 AM Eastern

About Vincerx Pharma Stock (NASDAQ:VINC)

Advanced

Key Stats

Today's Range
$0.0150
▼
$0.0150
50-Day Range
$0.0002
▼
$0.0151
52-Week Range
$0.00
▼
$0.07
Volume
250 shs
Average Volume
4,799 shs
Market Capitalization
$78.51 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company’s research has centered on treatments designed to selectively affect cancer cells while limiting exposure to healthy tissue.

Vincerx’s pipeline has included enitociclib, formerly known as VIP152, an oral, selective cyclin-dependent kinase 9 (CDK9) inhibitor investigated for hematologic malignancies such as diffuse large B-cell lymphoma and acute myeloid leukemia. The company has also developed small-molecule drug conjugates, including VIP236, as part of its efforts to deliver anticancer agents directly to tumors.

Founded in 2019 and headquartered in Palo Alto, California, Vincerx has operated primarily as a U.S.-based drug development company, conducting research and clinical activities through collaborations and clinical studies. Its programs and corporate strategy have evolved as it has advanced and evaluated its oncology pipeline.

AI Generated. May Contain Errors.

Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VINC Stock News Headlines

CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
Vincerx Pharma, Inc. (VINC) - Yahoo Finance
See More Headlines

VINC Stock Analysis - Frequently Asked Questions

Vincerx Pharma's stock was trading at $0.0126 on January 1st, 2026. Since then, VINC shares have increased by 19.0% and is now trading at $0.0150.

Vincerx Pharma, Inc. (NASDAQ:VINC) announced its earnings results on Thursday, August, 8th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($3.40) by $2.40.

Vincerx Pharma's stock reverse split on the morning of Tuesday, January 28th 2025.The 1-20 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vincerx Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and

Company Calendar

Last Earnings
8/08/2024
Today
9/24/2026
Next Earnings (Estimated)
11/10/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VINC
CIK
1796129
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.16 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-248.33%
Return on Assets
-132.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.17
Quick Ratio
2.17

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.50 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
5,234,000
Free Float
1,891,000
Market Cap
$78.51 thousand
Optionable
Not Optionable
Beta
1.41
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:VINC) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners